Key Findings
- Paltusotine is the first orally active, selective SSTR2 agonist approved for human use.
- Phase III PATHFNDR‑1 and PATHFNDR‑2 trials demonstrated significant IGF‑1 reduction in acromegaly patients.
- The drug is taken once daily and offers an alternative to injectable therapies.
Practical Outcomes
- Paltusotine could become a convenient option for medically lowering IGF‑1, but it requires a prescription and is only validated for acromegaly. Off‑label use for longevity or performance lacks safety data, so self‑experimentation should be approached with caution and medical supervision.
Summary
Paltusotine is a new oral pill that activates somatostatin receptor 2 to lower IGF‑1 levels. It’s the first once‑daily, non‑injectable drug approved in the US for treating acromegaly, a condition where IGF‑1 is too high. The approval is based on two large Phase III trials that showed it safely and effectively reduces IGF‑1 in patients who can’t have surgery. For biohackers it shows a convenient way to drop IGF‑1, but it’s a prescription medicine meant for a disease, not a proven anti‑aging tool.
Abstract
Paltusotine (PALSONIFY™) is a non-hormonal, orally active selective somatostatin receptor 2 (SSTR2) agonist that controls insulin-like growth factor-1 (IGF-1) levels, which are elevated in patients with acromegaly. It is the first approved once daily, orally administered treatment available for the treatment of acromegaly. Paltusotine received its first approval in the USA in September 2025, based on results from the PATHFNDR-1 and PATHFNDR-2 phase III clinical trials in patients with acromegaly. This article summarizes the milestones in the development of paltusotine leading to this first approval for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
Study Information
pubmed
2025
2025-11-26T00:00:00.000Z
10.1007/s40265-025-02260-3
7